Mandate

Vinge is advising Nytida in connection with merger with the Solhaga Group

January 25, 2016

Vinge is advising Nytida, which is part of Ambea, in connection with the merger with Solhagagruppen (the “Solhaga Group”).

Nytida intends to merge with the Solhaga Group. Nytida and the Solhaga Group possess considerable experience and expertise within the fields of functional impairment and the Solhaga Group specializes in the fields of neuropsychiatric and psychiatric impairment and reduced development. Both Nytida and the Solhaga Group conduct operations throughout a large part of Sweden and provide accommodation, schooling, short-term accommodation and daytime activities. The Solhaga Group also conducts operations in Norway.

Closing of the transaction is subject to the customary approval of the relevant competition authority.

Vinge’s team consisted of, among others, partners Christina Kokko, Jonas Johansson, Louise Brorson Salomon and Marcus Glader together with associates Linda Sengul, Maria Dahlin, Albert Wållgren, Anna-Maria Terzi, Emil Fahlén Godö and Anne Wijkman.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025